Researchers at South Korean lab make advance in fight against neglected tropical diseases

NewsGuard 100/100 Score

VOA News reports on a scientific breakthrough, which researchers call a "game changer" for developing new drugs, developed at Institut Pasteur Korea [IPK], a South Korean branch of the 124-year-old French research institute that is developing new drugs to combat diseases mainly affecting developing countries, including neglected tropical diseases (NTDs). "Combining imaging technology and biotechnology, scientists are now able to witness infections as they occur, in real time," VOA writes.

Ulf Nehrbass, chief executive officer of IPK, said that giant for-profit pharmaceutical companies "devote the bulk of their research budgets to finding blockbuster drugs, which could ring up billions of dollars in profits," but ignore the need for effective drugs targeting neglected diseases, VOA notes. "There have been breakthroughs in fighting some of the world's most serious and common diseases, thanks to start-up funding from South Korea's science ministry, along with contributions from non-government groups in the United States, France and other countries," VOA writes (Herman, 9/9).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses